Marcel Imwinkelried appointed as new CEO

   Siegfried AG / Key word(s): Personnel
   Marcel Imwinkelried appointed as new CEO
   10-Jul-2024 / 06:30 CET/CEST
   Release of an ad hoc announcement pursuant to Art. 53 LR
   The issuer is solely responsible for the content of this
   announcement.
     ____________________________________________________________

   
   The Board of Directors of Siegfried Holding AG has appointed
   Marcel Imwinkelried as the new CEO with effect as of September 1,
   2024. He will succeed Reto Suter, who has been leading the
   Siegfried Group as CEO ad interim since May 1, 2024, and will now
   focus again on his role as CFO.

   Marcel Imwinkelried (1967) joined the Siegfried Group in January
   2021 as Multi-Site Head for the Drug Products sites in Barberà
   del Vallès and El Masnou (Barcelona) and Irvine (California) and
   was appointed Chief Operating Officer Drug Products in October
   2021. Previously, he had worked for Novartis since 2005 in
   various roles with increasing responsibility and was appointed
   Global Head Technical Operations Solids in 2018.

   Andreas Casutt, Chairman of the Board of Directors: "Over the
   past three months, we have conducted intensive interviews with
   qualified external and internal candidates. Marcel impressed us
   not only with his professional track record, but also with his
   personality and strong leadership skills. As COO of our Drug
   Products division and a member of the Executive Board, he has
   already made significant contributions to Siegfried's success
   over the past three years. I am convinced that under his
   leadership Siegfried will continue its journey of growth."
   Contact

   Financial Analysts:     Media:
   Dr. Reto Suter          Peter Stierli
   CEO ad interim and CFO  Head Corporate Communications
   reto.suter@siegfried.ch peter.stierli@siegfried.ch
   Tel. +41 62 746 11 35   Tel. +41 62 746 15 51

Siegfried Holding AG

Untere Bruehlstrasse 4

CH-4800 Zofingen

   About Siegfried
   The Siegfried Group is a global life sciences company with sites
   in Switzerland, Germany, Spain, France, Malta, the USA and China.
   In 2023, the company achieved sales of CHF 1.272 billion and
   employed on 31.12.2023 more than 3700 people at twelve sites on
   three continents. Siegfried Holding AG is publicly listed on the
   SIX Swiss Exchange (SIX: SFZN).
   Siegfried is active in manufacturing pharmaceutical APIs (and
   their intermediates) as well as drug products (tablets, capsules,
   sterile vials, ampoules, cartridges and ointments) for the
   pharmaceutical industry and provides development services.
   Cautionary Statements Regarding Forward-Looking Statements
   This media release includes statements concerning the future.
   They are based on assumptions and expectations that may prove to
   be wrong. They should be considered with due caution as, by
   definition, they contain known and unknown risks, insecurities
   and other factors which could result in a difference in the
   actual results, financial situation, developments or the success
   of Siegfried Holding AG or Siegfried Group from the explicit or
   implicit assumptions made in these statements.

expect more

   Siegfried AG
   Untere Brühlstrasse 4
   4800 Zofingen, Switzerland
   +41 62 746 11 11
   info@siegfried.ch
   www.siegfried.ch

____________________________________________________________

   End of Inside Information
     ____________________________________________________________

   Language:    English
   Company:     Siegfried AG
                Untere Brühlstrasse 4
                4800 Zofingen
                Switzerland
   Phone:       +41 62 746 11 11
   E-mail:      info@siegfried.ch
   Internet:    https://www.siegfried.ch
   ISIN:        CH0014284498
   Listed:      SIX Swiss Exchange
   EQS News ID: 1942461

   End of Announcement EQS News Service
     ____________________________________________________________

1942461 10-Jul-2024 CET/CEST